Evaluation of hemostatic parameters in tumor-bearing dogs
Anjos, Denner Santos dosSantilli, JulianaVital, Aline FernandesOliveira, Jéssica Rodrigues deSobreira, Márcia Ferreira da RosaMagalhães, Geórgia ModéCalazans, Sabryna GouveiaFonseca-Alves, Carlos Eduardo
Background: Hemostatic alterations are commonly detected in canine cancer patients. However, few studies have described hemostatic dysfunction in dogs with different tumor subtypes. In Veterinary Medicine, the state of hypercoagulability is hardly diagnosed alive, since laboratory exams for evaluate hemostatic function are not always requested. Due to importance of homeostatic disorders in cancer patients, this study aimed to evaluate hemostatic alterations such as platelet count, activated partial thromboplastin time (aPTT), prothrombin time (PT) and fibrinogen in tumor-bearing dogs.Materials, Methods & Results: From the 55 dogs evaluated, 30 had mammary carcinoma, 6 visceral hemangiosarcoma, 9 high-grade cutaneous mast cell tumor and 10 multicentric lymphoma. The results were compared to a control group composed by 10 Beagle dogs. Thrombocytosis was observed in 26.6% (8/30) of mammary carcinoma group and thrombocytopenia in 10% (3/30). The patients with hemangiosarcoma and mast cell tumor did not reveal thrombocytosis, however, thrombocytopenia was present in 16.6% (1/6) and 33% (3/9), respectively. Three dogs with multicentric lymphoma showed thrombocytopenia and other three showed thrombocytosis. From patients with thrombocytosis, one was classified as severe thrombocytosis (1077 x 10³/µL). Therefore, there were no statistically significant associations between neoplasia group with control group (P > 0.05). Regarding the aPTT and PT evaluation, mammary carcinoma (P = 0.0005), hemangiosarcoma (P = 0.033) and mast cell tumor (P = 0.012) patients showed statistical difference for aPTT, while the evaluation for PT was not significant (P > 0.05). We grouped all patients as a tumor group and compared to the control group. It was possible to observe increased aPTT and PT in 89% (49/55) and 50.90% (28/55) respectively, in tumor group compared to normal.[...](AU)
Texto completo